We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Trial and error

6 June 2017 By Neil Unmack

A trial showed combining a new drug with the Swiss group’s Herceptin gave only a slight benefit to patients. That will make it harder to protect the blockbuster’s $7 bln of revenue from generic competitors. Roche could buy back shares, or rival drugmakers. Neither is cheap.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)